Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia
Stem Cells Translational Medicine · 11.02.2025 · 14 (2)
DOI: 10.1093/stcltm/szae094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 26.02.2025. Verfasst von Amin Cressman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Program, University of California at Davis, Sacramento, CA 95817, United States. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Ischemia, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TaiwanBio Therapeutics, MusculoSkeletal Clinical Learning Experience Program, UC Davis.
Abstract (Originalsprache)
Mesenchymal stromal cells (MSCs) have been tested in multiple clinical trials to treat peripheral artery disease, especially the more severe form called critical limb ischemia. However, MSCs have often not met the expected efficacy endpoints. We developed a more potent therapeutic by genetically modifying MSCs to overexpress Vascular Endothelial Growth Factor (VEGF-A165). Here, we report preclinical studies submitted to the Food and Drug Administration (FDA) as part of our Investigational New Drug submission package. In vitro studies included the characterization of cell banks, transcriptome and secretome analysis, and in vitro potency assays. In vivo studies using immune-deficient NSG mice include dose-finding efficacy studies using a Matrigel plug model, cell retention studies, measurements of circulating VEGF, and toxicology studies to rule out severe adverse events. Our results suggest both the safety and efficacy of MSC/VEGF and support a first-in-human clinical trial to test this new combined cell/gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell Program, University of California at Davis, Sacramento, CA 95817, United States.
- Taiwan Bio Therapeutics, 5F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County, Taiwan.
- GMP Facility, University of California at Davis, Sacramento, CA 95817, United States.
- Department of Cell Biology and Human Anatomy, University of California at Davis, Sacramento, CA 95817, United States.
Förderung
- TaiwanBio Therapeutics
- MusculoSkeletal Clinical Learning Experience Program
- UC Davis
- Vision Science Training Program
Zitieren
APA
Cressman, A., Le, B., Morales, D., Yen, W. S., Wu, F. J., Perotti, N. H., Fury, B., Nolta, J. A., & Fierro, F. A. (2025). Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia. Stem Cells Translational Medicine, 14(2). https://doi.org/10.1093/stcltm/szae094
Vancouver
Cressman A, Le B, Morales D, Yen WS, Wu FJ, Perotti NH, et al. Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia. Stem Cells Translational Medicine. 2025;14(2). doi:10.1093/stcltm/szae094
BibTeX
@article{Cressman2025,
author = {Cressman, Amin and Le, Bryan and Morales, David and Yen, Won-Shin and Wu, Fang-Ju and Perotti, Nicholas H and Fury, Brian and Nolta, Jan A and Fierro, Fernando A},
title = {Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia},
journal = {Stem Cells Translational Medicine},
year = {2025},
volume = {14},
number = {2},
doi = {10.1093/stcltm/szae094}
}
EUVIMED